tirzepatide cause bone loss and Density Frontiers | Bone mineral density

~6 days Half-Life (NEJM 2023) ~30 days Full Clearance (5 half-lives) 4-5 weeks Steady State Per Dose Once Weekly Dosing Interval Investigational Status Retatrutide is investigational and not FDA-approved as of April 2026

However, some people may experience mild side effects such as stomach upset, diarrhoea, and allergic reactions

When to contact your GP or seek urgent care: Persistent vomiting preventing fluid intake Severe abdominal pain Signs of dehydration (dark urine, dizziness, reduced urination) Unexplained weight loss or persistent nausea beyond the first few weeks Any concerns about side effects affecting daily life Regular monitoring through diabetes reviews allows healthcare professionals to assess treatment effectiveness, adjust doses appropriately, and identify any emerging safety concerns

Aktualnie Fellow Research Associate w Center for Labour and Just na Harvardzie